Example: Heart Attack

Clinical Trials Sponsored by Medigen Biotechnology Corporation

Total 9 results

    • NCT01675284
      Completed
      A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
      Conditions: Bird Flu; Avian Influenza; Influenza A(H5N1)
    • NCT01402908
      Terminated
      A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
      Conditions: Cancer; Liver Cancer; Hepatocellular Carcinoma
    • NCT00247728
      Completed
      PI-88 in Hepatocellular Carcinoma After Hepatectomy
      Conditions: Carcinoma, Hepatocellular
    • NCT00130442
      Completed
      Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
      Conditions: Melanoma
    • NCT00103389
      Completed
      Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
      Conditions: Lung Cancer
    • NCT00097851
      Completed
      Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)
      Conditions: Carcinoma, Non-Small-Cell Lung
    • NCT00073892
      Completed
      PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
      Conditions: Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific
    • NCT00068172
      Completed
      Study of PI-88 in Patients With Advanced Melanoma
      Conditions: Melanoma
    • NCT02293850
      Recruiting
      Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma
      Conditions: Carcinoma, Hepatocellular
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations